Residual Nodal Disease on Axillary US After Chemotherapy

Residual Nodal Disease on Axillary US After Chemotherapy is organized by American Roentgen Ray Society (ARRS).

Date of issuance: February 22, 2018
Date of expiration: February 21, 2021

Target Audience:
The target audience for this activity is readers of the AJR and radiologists at all training levels with an interest in residual nodal disease.
 
Accreditation:
Designation Statement
The ARRS designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The ARRS designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ and 1 American Board of Radiology©, MOC Part II, Self-Assessment CME (SA-CME.) Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Need:
AJR articles fulfill educational needs at all practice levels by addressing new research and studies, reviewing standards of care and addressing clinical practice and educational needs. Needs sources for the AJR include clinical practice guidelines, peer-reviewed literature, and expert defined needs.
 
Goals and Objectives:
After completing the material in this article, the learner should be able to:
• Determine lymph node features on axillary ultrasound images after neoadjuvant chemotherapy that are associated with residual nodal disease in patients with initial biopsy-proven node-positive breast cancer; and
• Discuss the usefulness of axillary ultrasound after neoadjuvant chemotherapy for nodal response assessment.

Additional details will be posted as soon as they are available.